Form 4: Blueprint Medicines CEO Disposes of All Equity Following Sanofi Acquisition

Blueprint Medicines Corp's Chief Executive Officer, Kate Haviland, disposed of all common stock, restricted stock units, performance stock units, and stock options as a result of Sanofi's acquisition of the company.

Summary

• Blueprint Medicines Corp (BPMC) was acquired by Sanofi, a French societe anonyme, through its subsidiaries Aventis Inc. and Rothko Merger Sub, Inc.
• The acquisition was completed via a tender offer, where Rothko Merger Sub, Inc. acquired all outstanding common stock of Blueprint Medicines Corp.
• The offer consideration for each share of common stock was $129.00 in cash (Cash Offer Price) plus one contractual contingent value right (CVR), representing the right to receive contingent payments upon the achievement of certain milestones.
• On July 17, 2025, the merger became effective, with Blueprint Medicines Corp surviving as an indirect wholly-owned subsidiary of Sanofi.
• Reporting Person Kate Haviland, CEO and Director, disposed of 295,139 shares of common stock that originated from performance-based vesting conditions (PSUs) and 224,410 shares from restricted stock units (RSUs), as well as 70,729 shares of common stock that were tendered.
• An additional 129,210 shares of common stock were acquired by the reporting person, representing PSUs that were deemed earned based on performance conditions.
• All outstanding stock options held by the reporting person, with exercise prices ranging from $16.28 to $100.13, became fully vested and were cancelled.
• These PSUs, RSUs, and stock options were converted into the Offer Consideration (cash and CVRs), with 50% of awards issued in calendar year 2025 converting into cash-based awards subject to continued vesting plus one CVR per share.
• Following these transactions, Kate Haviland's beneficial ownership of Blueprint Medicines Corp common stock and derivative securities is 0.

Sentiment

Score: 7

Explanation: The sentiment is positive for former shareholders who received a premium for their shares and potential future value from CVRs. For the company, it represents a successful acquisition outcome, albeit the end of its independent public status. The insider's transactions are a neutral, expected outcome of the merger.

Positives

• The completion of the merger provides a clear exit and value realization for Blueprint Medicines Corp shareholders at a Cash Offer Price of $129.00 per share.
• Shareholders also received one Contingent Value Right (CVR) per share, offering potential future payments based on milestone achievements.
• All outstanding stock options held by the reporting person became fully vested upon the effective time of the merger, allowing for their conversion into cash and CVRs.

Negatives

• Blueprint Medicines Corp ceased to be an independent publicly traded company, becoming an indirect wholly-owned subsidiary of Sanofi.
• The reporting person, Kate Haviland, no longer holds direct equity or derivative securities in the former public entity.

Risks

• The value of the Contingent Value Rights (CVRs) is dependent on the achievement of specific future milestones, introducing uncertainty regarding their ultimate payout.
• For 50% of PSUs, RSUs, and stock options issued in calendar year 2025, the conversion to cash-based awards is subject to continued vesting, meaning the full value is not immediately realized and depends on continued employment or other conditions.

Future Outlook

Blueprint Medicines Corp is now an indirect wholly-owned subsidiary of Sanofi, and its independent public market outlook has concluded. Future financial outcomes for former shareholders holding CVRs will depend on the achievement of specified contingent milestones.

Industry Context

This acquisition is characteristic of the pharmaceutical and biotechnology industry, where larger companies frequently acquire smaller, innovative firms to expand their pipeline, technology, or market presence. Sanofi's acquisition of Blueprint Medicines Corp indicates a strategic interest in Blueprint's assets and capabilities.

Stakeholder Impact

• Shareholders: Received $129.00 cash per share plus one CVR, realizing value from their investment.
• Employees (including management): Equity awards were converted into cash and CVRs, with some subject to continued vesting, impacting their compensation structure and future incentives within the new ownership structure.
• Company (Blueprint Medicines Corp): Ceased to be an independent public entity, becoming a wholly-owned subsidiary of Sanofi, leading to integration into Sanofi's operations.

Next Steps

• Achievement and reporting of milestones related to the Contingent Value Rights (CVRs) for former shareholders.
• Continued vesting of cash-based awards for certain employees, including the reporting person, that originated from 2025 equity grants.

Key Dates

Keywords

Blueprint Medicines, BPMC, Sanofi, Merger, Acquisition, Tender Offer, Form 4, Insider Trading, Stock Options, RSUs, PSUs, Contingent Value Right, CVR, Pharmaceutical, Biotechnology